Loading data for XFOR — first visit, this takes a few seconds.

Preisalarm

X4 Pharmaceuticals Inc. (XFOR)

NasdaqCM: XFOR · Echtzeitkurs · USD

4.20

-0.01 (-0.24%)

Zum Schluss: Aug 19, 2026, 3:20 PM

-0.24% (1D)

Keine Daten verfügbar

Geld	3.08
Marktkapitalisierung	418.89 Mio
Umsatz (TTM)	15.85 Mio
Nettogewinn (TTM)	-90.14 Mio
Beta	0.39
EPS (ttm)	1.43
KGV (TTM)	2.95
Forward-KGV	-5.6
KBV (TTM)	2.61
KUV (TTM)	26.43
Earnings Date	Nov 5, 2026

Brief	5.4
Volumen	184,249
Ø Vol. (20D)	750,170
Eröffnung	4.25
Vortagesschluss	4.21
Tagesspanne	4.20 - 4.35
52-Wk Range	2.69 - 4.83
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über XFOR

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agre...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Nov 16, 2017

Mitarbeiter 45

Börse NasdaqCM

Tickersymbol XFOR

Website https://www.x4pharma.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von X4 Pharmaceuticals 35.11 Mio, ein Anstieg von 1,273.21% im Vergleich zum Vorjahr (2.56 Mio). Der Gewinn lag bei -79.2 Mio, ein Anstieg von 111.48 %.

Finanzberichte

Gewinnüberraschung

X4 Pharmaceuticals hat die Quartalszahlen am Aug 6, 2026 veröffentlicht:

Umsatz von $8.81 Mio verfehlt die Erwartungen um $0, mit 346.33% Wachstum im Jahresvergleich.

EPS von -0.13 übertrifft die Erwartungen um 0.05, mit 96.25% Wachstum im Jahresvergleich.

Nächste Ergebnisveröffentlichung

X4 Pharmaceuticals Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Nov 5, 2026, während der Handelszeiten.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 1 Woche · Zacks

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

vor 1 Woche · Zacks

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

vor 3 Monaten · Simply Wall St.

How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress

X4 Pharmaceuticals has seen its modeled fair value price target move from US$8.00 to US$11.67, a sizable uplift that puts more focus on what the current share price is really discounting. Analysts are...

vor 3 Monaten · Zacks

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could...

vor 3 Monaten · Zacks

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seite 1 von 2

X4 Pharmaceuticals Inc. (XFOR)